Tag:
Selecta Biosciences
Latest Headlines
Latest Headlines
Exclusive: MIT's Langer, Farokhzad launch combination-med biotech
Serial biotech entrepreneurs Robert Langer and Omid Farokhzad are joining up with MIT's Dr. Stephen Lippard to launch a new drug developer--Blend Therapeutics--which will concentrate on the
Developer looks to nanoparticles for smoking cessation vaccine
Last week, Selecta Biosciences, a 2011 Fierce 15 company , announced that it has started a Phase I trial of a synthetic nanoparticle vaccine for smoking cessation. The shot, called SEL-068, is
Selecta starts trial of synthetic nano-vaccine for smoking
Boston-based Selecta Biosciences, a 2011 Fierce 15 winner , has kicked off a Phase I trial of nicotine vaccine SEL-068 for smoking cessation and relapse prevention. The company is touting its trial as
Russian fund leads $94.5M investment in two Langer biotechs
A pair of Boston-area biotechs focused on some cutting-edge bionanotechnology inspired by MIT's prolific Bob Langer is splitting a $94.5 million investment windfall spearheaded by RusNano, a
UPDATED: Selecta teams with diabetes foundation on Type 1 vaccine
Watertown, MA-based Selecta Biosciences , the biotech brainchild of MIT's prolific Bob Langer, is teaming up with the Juvenile Diabetes Research Foundation on a synthetic nanoparticle vaccine program
Selecta gets a new CEO, $3M for nicotine vax program
Selecta Biosciences has turned to a veteran of the pharma world to lead it through the startup phase. Werner Cautreels, who helmed Solvay Pharmaceuticals through its $6.6 billion sale to Abbott in
Former Solvay CEO moves to Selecta
Former Solvay CEO Werner Cautreels has taken the reins at Selecta Biosciences, a Watertown, MA-based developer of synthetic nanoparticle vaccines and immunotherapies. Cautreels was CEO at Solvay when
Money comes calling at Selecta Biosciences
Selecta Biosciences wasn't out looking for money--but it found them nevertheless. Just a little more than a year after hauling in a $15.1 million Series B round , the developer has raised a similar
Selecta Biosciences raises $15.1 in Series B
Selecta Biosciences has gained $15.1 million in a Series B financing round. Existing investors Polaris Venture Partners and Flagship Ventures led the round, joined by NanoDimension and immunologist
